A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma.
Alain Patrick AlgaziJulia RotowChristian PoschSusana Ortiz-UrdaAlyson PelayoPamela N MunsterAdil DaudPublished in: Pigment cell & melanoma research (2019)